JP2004521066A - 併用療法用ビトロネクチン受容体アンタゴニスト医薬 - Google Patents
併用療法用ビトロネクチン受容体アンタゴニスト医薬 Download PDFInfo
- Publication number
- JP2004521066A JP2004521066A JP2002503332A JP2002503332A JP2004521066A JP 2004521066 A JP2004521066 A JP 2004521066A JP 2002503332 A JP2002503332 A JP 2002503332A JP 2002503332 A JP2002503332 A JP 2002503332A JP 2004521066 A JP2004521066 A JP 2004521066A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- aryl
- methyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC1=C(C2)*2C(*)*N1 Chemical compound CC1=C(C2)*2C(*)*N1 0.000 description 31
- YECJUZIGFPJWGQ-UHFFFAOYSA-N Cc(cc1C)cc(C)c1S(N)(=O)=O Chemical compound Cc(cc1C)cc(C)c1S(N)(=O)=O YECJUZIGFPJWGQ-UHFFFAOYSA-N 0.000 description 2
- GXUHNMAKFSAKJX-LBPRGKRZSA-N CC(C)(C)OC(N[C@@H](CCC(Oc(c(F)c(cc1F)F)c1F)=O)C(Oc(c(F)c(cc1F)F)c1F)=O)=O Chemical compound CC(C)(C)OC(N[C@@H](CCC(Oc(c(F)c(cc1F)F)c1F)=O)C(Oc(c(F)c(cc1F)F)c1F)=O)=O GXUHNMAKFSAKJX-LBPRGKRZSA-N 0.000 description 1
- HOKWAZBYIVDJSE-UVBKOFRMSA-N CC/C(/C)=C(\NCc(cc1N(CCCNC([C@H](CS(O)(=O)=O)NC(CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)=O)=O)C=C2C(NC[C@@H](C(O)=O)NS(c3c(C)cc(C)cc3C)(=O)=O)=O)ccc1C2=O)/N/C=C\C Chemical compound CC/C(/C)=C(\NCc(cc1N(CCCNC([C@H](CS(O)(=O)=O)NC(CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)=O)=O)C=C2C(NC[C@@H](C(O)=O)NS(c3c(C)cc(C)cc3C)(=O)=O)=O)ccc1C2=O)/N/C=C\C HOKWAZBYIVDJSE-UVBKOFRMSA-N 0.000 description 1
- WTCHZIJPDSCPBA-UHFFFAOYSA-N CN(C=C1C(NCCC(OC)=O)=O)c2cc(CN)ccc2C1=O Chemical compound CN(C=C1C(NCCC(OC)=O)=O)c2cc(CN)ccc2C1=O WTCHZIJPDSCPBA-UHFFFAOYSA-N 0.000 description 1
- TXZZZTMNZSTIEZ-AWEZNQCLSA-N CN(C=C1C(NC[C@@H](C(OC)=O)N)=O)c(cc(CNc2ncc[nH]2)cc2)c2C1=O Chemical compound CN(C=C1C(NC[C@@H](C(OC)=O)N)=O)c(cc(CNc2ncc[nH]2)cc2)c2C1=O TXZZZTMNZSTIEZ-AWEZNQCLSA-N 0.000 description 1
- CGZDMVXQAQGIMW-UHFFFAOYSA-N Cc(cc(cc1C)OCCCC(NCCNC(C(CS(O)(=O)=O)NC(CCC(C=O)N)=O)=O)=O)c1S(=O)=O Chemical compound Cc(cc(cc1C)OCCCC(NCCNC(C(CS(O)(=O)=O)NC(CCC(C=O)N)=O)=O)=O)c1S(=O)=O CGZDMVXQAQGIMW-UHFFFAOYSA-N 0.000 description 1
- SFLUJIXMVIVXRW-UHFFFAOYSA-N Cc(cc1C)cc(C)c1S(N=C)(=O)=O Chemical compound Cc(cc1C)cc(C)c1S(N=C)(=O)=O SFLUJIXMVIVXRW-UHFFFAOYSA-N 0.000 description 1
- QUXLCYFNVNNRBE-UHFFFAOYSA-N Cc1nc(N)ccc1 Chemical compound Cc1nc(N)ccc1 QUXLCYFNVNNRBE-UHFFFAOYSA-N 0.000 description 1
- ZWXAVIBKKKTERN-UHFFFAOYSA-N Cc1nnc(C(F)(F)F)[nH]1 Chemical compound Cc1nnc(C(F)(F)F)[nH]1 ZWXAVIBKKKTERN-UHFFFAOYSA-N 0.000 description 1
- WIUUFNSNNMFKSV-LREOWRDNSA-N NC/C=C/N(C=C1C(NCCC(O)=O)=O)c(cc(CN)cc2)c2C1=O Chemical compound NC/C=C/N(C=C1C(NCCC(O)=O)=O)c(cc(CN)cc2)c2C1=O WIUUFNSNNMFKSV-LREOWRDNSA-N 0.000 description 1
- PECYZEOJVXMISF-REOHCLBHSA-N NC[C@@H](C(O)=O)N Chemical compound NC[C@@H](C(O)=O)N PECYZEOJVXMISF-REOHCLBHSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21321000P | 2000-06-21 | 2000-06-21 | |
| PCT/US2001/019793 WO2001097848A2 (fr) | 2000-06-21 | 2001-06-21 | Agents pharmaceutiques antagonistes du recepteur de vitronectine, a utiliser en polytherapie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004521066A true JP2004521066A (ja) | 2004-07-15 |
| JP2004521066A5 JP2004521066A5 (fr) | 2008-08-14 |
Family
ID=22794168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002503332A Pending JP2004521066A (ja) | 2000-06-21 | 2001-06-21 | 併用療法用ビトロネクチン受容体アンタゴニスト医薬 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1307226B1 (fr) |
| JP (1) | JP2004521066A (fr) |
| CN (1) | CN1582166A (fr) |
| AT (1) | ATE414541T1 (fr) |
| AU (2) | AU7296501A (fr) |
| BR (1) | BR0111880A (fr) |
| CA (1) | CA2412854C (fr) |
| DE (1) | DE60136632D1 (fr) |
| IL (1) | IL152941A0 (fr) |
| MX (1) | MXPA02012750A (fr) |
| NZ (1) | NZ522925A (fr) |
| WO (1) | WO2001097848A2 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| AU2001258095A1 (en) | 2000-05-08 | 2001-11-20 | The University Of British Columbia | Drug delivery systems for photodynamic therapy |
| AU2001271435A1 (en) * | 2000-06-21 | 2002-01-02 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| EP1572639A4 (fr) | 2002-01-24 | 2006-08-09 | Barnes Jewish Hospital | Agents d'imagerie ciblant des integrines |
| EP1475105A1 (fr) * | 2003-05-09 | 2004-11-10 | Schering AG | Radiopharmaceutique visant le tissu osseux et composé interagissant avec la tubuline pour une radiothérapie combinatoire. |
| ATE449614T1 (de) * | 2003-05-12 | 2009-12-15 | Lantheus Medical Imaging Inc | Vitronectin rezeptorantagonisten und ihre verwendung als radiopharmazeutika |
| EP3101012A1 (fr) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | Nouveaux composés de chélate de gadolinium pour une utilisation dans l'imagerie par résonance magnétique |
| CA3044877A1 (fr) | 2016-11-28 | 2018-05-31 | Bayer Pharma Aktiengesellschaft | Composes de chelate de gadolinium a relaxivite elevee pour utilisation dans l'imagerie par resonance magnetique |
| US11090395B2 (en) * | 2018-09-14 | 2021-08-17 | SeeCure Taiwan Co., Ltd. | Composition for cross talk between estrogen receptors and cannabinoid receptors |
| SG11202104657RA (en) | 2018-11-23 | 2021-06-29 | Bayer Ag | Formulation of contrast media and process of preparation thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998023608A1 (fr) * | 1996-11-27 | 1998-06-04 | Dupont Pharmaceuticals Company | Nouveaux antagonistes des recepteurs de l'integrine |
| JP2001512666A (ja) * | 1997-08-07 | 2001-08-28 | トーマス・ジェファーソン・ユニバーシティ | 結腸直腸癌細胞に特異的に結合する組成物およびその使用法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6093382A (en) * | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| CN1356913A (zh) * | 1998-12-18 | 2002-07-03 | 杜邦药品公司 | 玻连蛋白受体拮抗剂药物 |
| AU7002501A (en) * | 2000-06-21 | 2002-01-02 | Du Pont Pharm Co | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| CA2413328A1 (fr) * | 2000-06-21 | 2001-12-27 | Milind Rajopadhye | Produits pharmaceutiques pour l'imagerie de troubles angiogeniques |
| AU2001271435A1 (en) * | 2000-06-21 | 2002-01-02 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| EP1311301A2 (fr) * | 2000-07-06 | 2003-05-21 | Bristol-Myers Squibb Pharma Company | Compositions radiopharmaceutiques stables et procedes de fabrication de ces compositions |
-
2001
- 2001-06-21 CN CNA018144306A patent/CN1582166A/zh active Pending
- 2001-06-21 CA CA2412854A patent/CA2412854C/fr not_active Expired - Fee Related
- 2001-06-21 AU AU7296501A patent/AU7296501A/xx active Pending
- 2001-06-21 MX MXPA02012750A patent/MXPA02012750A/es not_active Application Discontinuation
- 2001-06-21 NZ NZ522925A patent/NZ522925A/en unknown
- 2001-06-21 EP EP01952180A patent/EP1307226B1/fr not_active Expired - Lifetime
- 2001-06-21 BR BRPI0111880-3A patent/BR0111880A/pt not_active IP Right Cessation
- 2001-06-21 AT AT01952180T patent/ATE414541T1/de not_active IP Right Cessation
- 2001-06-21 WO PCT/US2001/019793 patent/WO2001097848A2/fr active IP Right Grant
- 2001-06-21 IL IL15294101A patent/IL152941A0/xx unknown
- 2001-06-21 DE DE60136632T patent/DE60136632D1/de not_active Expired - Lifetime
- 2001-06-21 JP JP2002503332A patent/JP2004521066A/ja active Pending
- 2001-06-21 AU AU2001272965A patent/AU2001272965C1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998023608A1 (fr) * | 1996-11-27 | 1998-06-04 | Dupont Pharmaceuticals Company | Nouveaux antagonistes des recepteurs de l'integrine |
| JP2001512666A (ja) * | 1997-08-07 | 2001-08-28 | トーマス・ジェファーソン・ユニバーシティ | 結腸直腸癌細胞に特異的に結合する組成物およびその使用法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2412854C (fr) | 2010-08-17 |
| WO2001097848A2 (fr) | 2001-12-27 |
| WO2001097848A3 (fr) | 2003-03-13 |
| BR0111880A (pt) | 2006-04-25 |
| DE60136632D1 (de) | 2009-01-02 |
| AU7296501A (en) | 2002-01-02 |
| NZ522925A (en) | 2006-08-31 |
| IL152941A0 (en) | 2003-06-24 |
| AU2001272965C1 (en) | 2006-06-29 |
| ATE414541T1 (de) | 2008-12-15 |
| CA2412854A1 (fr) | 2001-12-27 |
| EP1307226B1 (fr) | 2008-11-19 |
| MXPA02012750A (es) | 2004-07-30 |
| AU2001272965B2 (en) | 2005-11-17 |
| CN1582166A (zh) | 2005-02-16 |
| EP1307226A2 (fr) | 2003-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6743412B2 (en) | Vitronectin receptor antagonist pharmaceuticals | |
| US6322770B1 (en) | Indazole vitronectin receptor antagonist pharmaceuticals | |
| AU2001270025A1 (en) | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy | |
| WO2001098294A2 (fr) | Produits pharmaceutiques d'antagonistes recepteurs de la vitronectine utilises en polytherapie | |
| US6524553B2 (en) | Quinolone vitronectin receptor antagonist pharmaceuticals | |
| US6838074B2 (en) | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | |
| WO2001097861A2 (fr) | Agents pharmaceutiques antagonistes du recepteur de la vitronectine destines a etre utilises dans une therapie combinee | |
| US7138104B2 (en) | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | |
| US6511649B1 (en) | Vitronectin receptor antagonist pharmaceuticals | |
| EP1307226B1 (fr) | Agents pharmaceutiques antagonistes du recepteur de vitronectine | |
| AU2002331042A1 (en) | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | |
| US7090828B2 (en) | Vitronectin receptor antagonist pharmaceuticals | |
| AU2001272965A1 (en) | Vitronectin receptor antagonist pharmaceuticals | |
| US7332149B1 (en) | Vitronectin receptor antagonist pharmaceuticals | |
| MXPA01006151A (en) | Vitronectin receptor antagonist pharmaceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080623 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080623 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111115 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120417 |